Abstract
Background: Left atrial appendage closure is a non-pharmacological alternative for stroke prevention in high-risk non-valvular atrial fibrillation patients, but has not been widely studied in Asian patients. The prospective WASP registry assessed real-world outcomes for patients undergoing WATCHMAN implant in the Asia-Pacific region. Methods: Data were collected from consecutive patients across 9 centres. Major endpoints included procedural success, safety and long-term outcomes including occurrence of bleeding, stroke/transient ischaemic attack/systemic embolism and all-cause mortality. Results: Subjects (n = 201) had a mean age of 70.8 ± 9.4 years, high stroke risk (CHA 2 DS 2 -VASc: 3.9 ± 1.7), elevated bleeding risk (HAS-BLED: 2.1 ± 1.2) with 53% patients from Asian countries. Successful implantation occurred in 98.5% of patients; 7-day device/procedure-related SAE rate was 3.0%. After 2 years of follow-up, the rates of ischaemic stroke/TIA/SE and major bleeding were 1.9 and 2.2 per 100-PY, respectively, representing relative reductions of 77% and 49% versus expected rates per risk scores. The relative risk reductions versus expected rates were more pronounced in Asians vs. Non-Asians (89% vs 62%; 77% vs 14%). Other significant findings included larger mean LAA ostium diameter for Asians vs. Non-Asians (23.4 ± 4.1 mm vs. 21.2 ± 3.2 mm, p < 0.001) and hence requirement for larger median device size (27 mm for Asians, 24 mm for non-Asians [p < 0.0001]). Conclusion: Real-world experience of left atrial appendage closure with WATCHMAN has demonstrated low peri-procedural risk, and long-term efficacy for stroke and bleeding prevention in a primarily Asian cohort.
Original language | English |
---|---|
Article number | 100358 |
Journal | IJC Heart and Vasculature |
Volume | 23 |
DOIs | |
Publication status | Published - 2019 Jun |
Bibliographical note
Funding Information:Work was supported by Boston Scientific Inc., Marlboro, MA, USA. PS is supported by a Practitioner Fellowship from the National Health and Medical Research Council of Australia and by National Heart Foundation of Australia.
Funding Information:
Work was supported by Boston Scientific Inc., Marlboro, MA, USA. PS is supported by a Practitioner Fellowship from the National Health and Medical Research Council of Australia and by National Heart Foundation of Australia .
Publisher Copyright:
© 2019 The Authors
All Science Journal Classification (ASJC) codes
- Cardiology and Cardiovascular Medicine